Company's CE Approved Rapid HIV Tests Transitioned to New 3-Step Procedure and Global Reveal Brand
HALIFAX, May 25 /CNW/ - MedMira Inc., ("MedMira") (TSX Venture: MIR, NASDAQ: MMIRF), a developer of rapid diagnostic technology and solutions, today announced that the Company's Reveal Rapid HIV Test is now one of three rapid HIV tests listed by the National Health Services (NHS) Supply Chain in the United Kingdom, and the only one able to address both point of care and laboratory testing requirements. The NHS Supply Chain manages the procurement and delivery of healthcare products for over 600 hospitals and healthcare organizations in the UK.
"This is another step forward in our continuing sales and marketing thrust in Europe. Inclusion on the NHS list is key to accessing new opportunities to participate in healthcare tenders and provide our rapid tests to both the private and public sector healthcare organizations," said Hermes Chan, CEO, MedMira Inc. "Once again progress in developing market opportunities was achieved through our strategic partner network. Working with our partner Vitest and one of its local associates in the UK, Home Health, we were able to accelerate the introduction of Reveal into the NHS system which brings the most innovative products to healthcare providers and their patients in the UK."
Vitest AG, MedMira's strategic marketing partner for Europe and Africa, is ramping up initiatives in Europe to develop greater market penetration for the Reveal Rapid HIV Test. Supporting these efforts is CE approval of a new, easier to use, 3-step test procedure as well as the recent transition of the Company's CE-approved products to the Reveal brand, further building on the strength of this brand in the North American and international markets. Setting Reveal apart from competitors in the European market is the offer of two distinct formats, one geared for point of care testing and the other designed for laboratories and programs with batch testing requirements.
"Obtaining the NHS listing for Reveal demonstrates significant progress in our plan to build market share in the UK and other countries in Europe. As one of three listed rapid HIV tests with the NHS we are now able to bid on public tender opportunities," said Nicholas Dellaportas, Director of International Business and Sales, Vitest AG. "Building awareness of the Reveal rapid HIV test with the NHS will also benefit our marketing and business development activities in Africa as the NHS provides funding and support to many awareness campaigns where testing is a focus."
MedMira is a leading developer and manufacturer of flow-through rapid diagnostics. The company's tests provide hospitals, labs, clinics and individuals with reliable, rapid diagnosis for diseases such as HIV and hepatitis C in just three minutes. The company's tests are sold under the Reveal(R), Multiplo(TM) and Miriad brands in global markets. MedMira's rapid HIV test is the only one in the world to achieve regulatory approvals in Canada, the United States, China and the European Union. MedMira's corporate offices and manufacturing facilities are located in Halifax, Nova Scotia, Canada. For more information visit MedMira's website at www.medmira.com.
This news release contains forward-looking statements, which involve risk and uncertainties and reflect the company's current expectation regarding future events. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings.
The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement.
SOURCE MedMira Inc.
For further information: For further information: MedMira Contact: Andrea Young, Corporate Communications, (902) 450-1588, email@example.com